- Home
- ASIX vs FDMT Comparison
ASIX vs FDMT Comparison
Compare ASIX & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASIX | FDMT |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.0M | 513.6M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ASIX | FDMT |
|---|---|---|
| Price | $18.68 | $8.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $26.00 | ★ $34.13 |
| AVG Volume (30 Days) | 356.6K | ★ 725.8K |
| Earning Date | 05-22-2026 | 04-13-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $1,684,625,000.00 | $37,000.00 |
| Revenue This Year | $3.53 | $21,227.03 |
| Revenue Next Year | N/A | $161.87 |
| P/E Ratio | $10.93 | ★ N/A |
| Revenue Growth | ★ 45.49 | N/A |
| 52 Week Low | $14.10 | $2.24 |
| 52 Week High | $25.53 | $12.34 |
Technical Indicators
Market Signals| Indicator | ASIX | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 46.76 |
| Support Level | $17.54 | $8.11 |
| Resistance Level | $19.68 | $8.80 |
| Average True Range (ATR) | 1.18 | 0.56 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 38.07 | 25.33 |
Price Performance
Historical ComparisonAbout ASIX AdvanSix Inc.
AdvanSix Inc is a diversified chemistry company playing a critical role in international supply chains, innovating and delivering essential products for customers across a wide variety of end markets and applications that touch people's lives, including building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, and electronics. The company's key products include Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates. The majority of sales are from Plant Nutrients products. The company operates in the United States and internationally, with the majority of revenue coming from the United States.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.